106 reports of this reaction
1.2% of all REGADENOSON reports
#20 most reported adverse reaction
SYNCOPE is the #20 most commonly reported adverse reaction for REGADENOSON, manufactured by Astellas Pharma US, Inc.. There are 106 FDA adverse event reports linking REGADENOSON to SYNCOPE. This represents approximately 1.2% of all 8,610 adverse event reports for this drug.
REGADENOSON has an overall safety score of 78 out of 100. Patients taking REGADENOSON who experience syncope should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SYNCOPE is a less commonly reported adverse event for REGADENOSON, but still significant enough to appear in the safety profile.
In addition to syncope, the following adverse reactions have been reported for REGADENOSON:
The following drugs have also been linked to syncope in FDA adverse event reports:
SYNCOPE has been reported as an adverse event in 106 FDA reports for REGADENOSON. This does not prove causation, but indicates an association observed in post-market surveillance data.
SYNCOPE accounts for approximately 1.2% of all adverse event reports for REGADENOSON, making it a notable side effect.
If you experience syncope while taking REGADENOSON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.